CuraTeQ Biologics receives approval for Biosimilar Zefylti
CuraTeQ Biologics, an Aurobindo Pharma subsidiary, secured UK MHRA marketing authorisation for Zefylti, its filgrastim biosimilar, following EU approval in February 2025. This marks CuraTeQ's second biosimilar approval in the UK, after Bevqolva in December 2024. This authorisation expands access to a more affordable version of filgrastim for patients in the UK.